Revealing tissue microstructure in the brain gray matter in Alzheimer's disease using in vivo high-gradient diffusion MRI

使用体内高梯度扩散 MRI 揭示阿尔茨海默病大脑灰质的组织微观结构

• 批准号: 10254657
• 负责人: Hong Hsi Lee
• 金额: $ 42万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-14 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10254657
• 关键词: 3-Dimensional; Address; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Amyloid; Amyloid beta-Protein; Applications Grants; Award; Axon; Biological Markers; Blood; Brain; Cell Size; Cells; Cerebrospinal Fluid Proteins; Clinic; Clinical; Computer software; Data; Dementia; Development; Diagnostic; Diffusion; Diffusion Magnetic Resonance Imaging; Disease; Disease Progression; Doctor of Philosophy; Early Diagnosis; Early identification; Electron Microscopy; Ensure; Evaluation; Faculty; Family Caregiver; Future; General Hospitals; Geometry; Goals; High Performance Computing; Histologic; Histology; Histopathology; Human; Imaging Techniques; Impaired cognition; Interdisciplinary Study; Intervention; Joints; Knowledge; Laboratories; Leadership; Magnetic Resonance Imaging; Massachusetts; Measurement; Measures; Medicine; Mentorship; Microscopic; Microscopy; Monitor; Monte Carlo Method; Mus; Nerve Degeneration; Neurites; Neurodegenerative Disorders; Neurons; Onset of illness; Paper; Pathologic; Patients; Peer Review; Physics; Positioning Attribute; Positron-Emission Tomography; Postdoctoral Fellow; Presenile Alzheimer Dementia; Radiology Specialty; Research; Resolution; Resource Sharing; Risk; Running; Scientist; Structure; Symptoms; System; Techniques; Technology; Testing; Three-dimensional analysis; Time; Tissues; Training; Translating; Treatment Efficacy; United States; Validation; Varicosity; Work; aging population; base; bioimaging; biophysical model; brain tissue; career; career development; clinical translation; cluster computing; connectome; density; experience; experimental study; graduate student; gray matter; high dimensionality; high risk; imaging biomarker; imaging facilities; in vivo; innovative technologies; instructor; light microscopy; magnetic resonance imaging biomarker; medical schools; meetings; microCT; mild cognitive impairment; neuronal cell body; next generation; non-invasive imaging; novel; novel therapeutics; prognostic; protein biomarkers; research study; senior faculty; simulation; skills; success; tau Proteins; tau-1; theories; tool; treatment response; white matter; white matter change

Project Summary/Abstract Alzheimer’s disease (AD) accounts for about 70% of dementia cases, and the number of AD patients continues to grow substantially due to the worldwide phenomenon of population aging, prompting the call for innovative technologies that will enable the early identification of patients at risk and monitoring of disease progression and therapeutic response. There is a known sequence of pathological alterations that develop in Alzheimer’s disease (AD) long before frank cognitive decline, offering potential targets for early detection of disease onset with subsequent interventions. While volumetric MRI changes are useful to assess the presence of neurodegeneration, regional cortical volume loss is a relatively late structural marker of neurodegeneration in AD. On the other hand, diffusion MRI (dMRI) is a non-invasive imaging technique sensitive to pathological changes on the cellular level, at least three orders of magnitude below the nominal spatial resolution of conventional MRI. So far, most AD studies using dMRI have largely focused on white matter changes. However, on histopathology, AD is primarily a cortical disease. The ability to probe early microstructural changes in GM in vivo would open the door to assessing disease onset and progression, facilitating the development of disease- modifying therapy. This project will bridge the gap in understanding changes in GM tissue microstructure in AD and mild cognitive impairment (MCI) using a combination of tools in multiple domains, such as biophysical modeling, ex vivo and in vivo dMRI, and histological validation. We will address this multi-faceted research challenge through the following aims: Aim 1: Establish time-dependent dMRI measurements to evaluate the density of axonal varicosities, size of cell body (soma), and soma/neurite density using a high-gradient MRI system. By leveraging the very strong diffusion gradients on the current and next-generation Connectome MRI scanner, we will develop a novel technique for evaluating the tissue microstructure in healthy subjects, AD and MCI patients. Aim 2: Validate in vivo and ex vivo dMRI measures of axonal and soma structure via Monte Carlo simulations of diffusion and histological analysis in three-dimensional realistic substrates based on light and electron microscopy, and micro-CT data. Aim 3: Assess the correlation of GM microstructural parameters with cognitive dysfunction, amyloid and tau PET scans, and blood and cerebrospinal fluid protein biomarkers, such as amyloid beta, total and phosphorylated tau (P-tau 181 and P-tau 217). In summary, building on our previous success in assessing white matter microstructure using dMRI, our study in GM promises to provide reliable noninvasive imaging markers of neurodegeneration, facilitating our understanding of the mechanisms underlying the progression of AD. Ultimately, the quantification of GM microstructure will offer prognostic and confirmatory biomarkers for neurodegenerative diseases, facilitating the assessment of treatment efficacy with the emergence of new therapies for AD and related dementias.

项目摘要/摘要 阿尔茨海默氏病（AD）约占痴呆症病例的70％，并且AD患者的数量继续 由于人口衰老的全球现象，要大大成长，促使呼吁创新 将能够早期鉴定有风险和监测疾病进展的患者的技术 治疗反应。在阿尔茨海默氏病中发生了一系列已知的病理改变序列 （AD）早在坦率的认知下降之前就很早就提供了潜在的靶标，以提早发现疾病发作 随后的干预措施。尽管体积MRI变化对于评估存在很有用 神经变性，区域皮质体积损失是神经变性的相对晚期结构标记 广告。另一方面，扩散MRI（DMRI）是对病理敏感的无创成像技术 细胞水平的变化，至少低于标称空间分辨率的三个数量级 常规MRI。到目前为止，大多数使用DMRI的广告研究主要集中在白质变化上。然而， 关于组织病理学，AD主要是一种皮质疾病。探测GM早期微结构变化的能力 体内将打开评估疾病发作和进展的大门，支持疾病的发展 - 修改疗法。该项目将弥合理解AD中GM组织微观结构变化的差距 和轻度认知障碍（MCI），使用多种工具组合，例如生物物理 建模，离体和体内DMRI以及组织学验证。我们将解决这项多方面的研究 通过以下目的挑战：目标1：建立与时间相关的DMRI测量以评估 轴突静脉曲张的密度，细胞体的大小（SOMA）和SOMA/神经突密度使用高梯度MRI 系统。通过利用电流和下一代Connectome MRI上的非常强的扩散梯度 扫描仪，我们将开发一种新型技术，用于评估健康受试者，AD和 MCI患者。 AIM 2：通过蒙特卡洛验证轴突和SOMA结构的体内和Ex Vivo DMRI测量 基于光和三维现实底物中扩散和组织学分析的模拟 电子显微镜和Micro-CT数据。目标3：评估GM微结构参数与 认知功能障碍，淀粉样蛋白和tau PET扫描以及血液和脑脊液蛋白生物标志物，这种 作为淀粉样蛋白β，总和磷酸化的tau（p-tau 181和p-tau 217）。 总而言之，基于我们以前在使用DMRI评估白质微观结构的成功基础上 通用汽车的研究有望提供可靠的神经变性的无创成像标记，支持我们 了解AD进展的机制。最终，通用汽车的数量 微观结构将为神经退行性疾病提供预后和确认生物标志物，支持该疾病 评估治疗效率，并出现针对AD和相关痴呆症的新疗法的出现。